
    
      This is a pilot/feasibility study of memantine in severe traumatic brain injury (TBI)
      persons, employing a randomized, double-blind, placebo-controlled, design. Outcome
      evaluations will occur after 24 weeks of treatment (on medication) and 4 weeks after
      treatment discontinuation.
    
  